RxSight, Inc. (NASDAQ:RXST) Holdings Trimmed by Fmr LLC

Fmr LLC cut its holdings in RxSight, Inc. (NASDAQ:RXST) by 4.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,202,251 shares of the company’s stock after selling 52,078 shares during the quarter. Fmr LLC owned about 2.98% of RxSight worth $59,427,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Driehaus Capital Management LLC raised its holdings in shares of RxSight by 74.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after purchasing an additional 302,367 shares in the last quarter. Brown Capital Management LLC acquired a new position in RxSight in the third quarter worth approximately $26,813,000. Baillie Gifford & Co. increased its holdings in shares of RxSight by 17.0% in the third quarter. Baillie Gifford & Co. now owns 419,004 shares of the company’s stock valued at $20,711,000 after buying an additional 60,789 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of RxSight during the 2nd quarter valued at $19,512,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of RxSight by 28.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company’s stock worth $14,104,000 after acquiring an additional 62,507 shares in the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Shweta Maniar sold 3,782 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $173,518.16. Following the completion of the sale, the director now directly owns 10,902 shares in the company, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction on Friday, September 20th. The shares were sold at an average price of $53.19, for a total value of $164,889.00. Following the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $2,247,064.74. The trade was a 6.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 65,807 shares of company stock worth $3,202,275. 9.36% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on RXST shares. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Jefferies Financial Group assumed coverage on shares of RxSight in a research note on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Finally, UBS Group began coverage on shares of RxSight in a research report on Friday. They issued a “buy” rating and a $52.00 target price on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight currently has a consensus rating of “Buy” and a consensus price target of $63.63.

RxSight Trading Up 2.1 %

Shares of NASDAQ RXST opened at $43.15 on Friday. RxSight, Inc. has a one year low of $33.09 and a one year high of $66.54. The business has a 50-day moving average price of $48.11 and a two-hundred day moving average price of $51.81. The firm has a market capitalization of $1.74 billion, a PE ratio of -50.94 and a beta of 1.11.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.